A San Francisco-based artificial intelligence lab has administered bacteriophages designed by an AI model to a human patient for the first time, marking what Radical Numerics announced this week as an unprecedented step in translating computational biology into clinical practice. The bacteria-targeting viruses were created using Omnii-1, an AI model unveiled by the company this week, and given to a patient suffering from an antibiotic-resistant infection under a compassionate-use arrangement. The treatment represents the first instance of AI-generated phages being used in a human, though the company hasn't disclosed how the therapy performed or what specific infection the patient faced.
The AI-designed phage cocktail successfully wiped out the patient's antibiotic-resistant bacterial sample in laboratory tests before being administered, according to Radical Numerics. The company tested Omnii-1's capacity to predict which phages could infect Pseudomonas aeruginosa, a bacterium known to develop antibiotic resistance and trigger infections in burn patients, wound cases, and people with cystic fibrosis who experience chronic lung infections. The AI model matched the performance of a specialized prediction system when identifying phage-host interactions, though nothing in the research indicates the treated patient had a Pseudomonas aeruginosa infection. The company cited patient privacy concerns for withholding outcome data and emphasized that a single case doesn't establish general safety or effectiveness.
The company describes the treatment as "an important milestone in translating AI-designed biology from computational predictions and laboratory validation to clinical administration." Radical Numerics' approach builds on previous work by Stanford University and Arc Institute researchers who created AI-designed phages targeting E. coli bacteria, some of which outperformed their natural counterparts in lab settings. The company referenced this Stanford research in its own write-up, using similar methods to engineer bacteriophages through its proprietary AI model.
Bacteriophages offer potential advantages over conventional antibiotics because they target specific bacterial strains rather than killing beneficial gut bacteria along with harmful ones, a common problem with broad-spectrum antibiotic drugs. The need for alternatives has become urgent as antibiotic resistance poses a growing global health threat, with drug-resistant infections already causing substantial deaths worldwide. Radical Numerics aims to develop a process for designing and building phages tailored to individual bacterial infections, pushing the technology past laboratory experimentation even if the initial treatment doesn't completely eliminate the patient's infection.
The breakthrough arrives at a moment when traditional antibiotics are losing ground against evolving bacteria, and the race for new therapies has intensified across the pharmaceutical industry. If validated through broader clinical trials, AI-guided phage design could reshape how medicine approaches bacterial infections that no longer respond to existing drugs.